Cleveland Clinic (CC) and its partners Case Western Reserve University, Cincinnati Children's Hospital Medical Center, The Ohio State University and University of Cincinnati have a longstanding commitment and documented success in transitioning laboratory and clinical innovations into dramatic improvements in patient care, CC alone, via its commercialization arm CC Innovations (CCI), has generated 53 spin-off companies and $644 million in equity financing in the past decade;however CCI has a focus on more mature programs and does not reach back into the research pipeline. Also, contributing to commercialization success of the applicant institutions has been the establishment of the state-funded Global Cardiovascular Innovation Center (GCIC) that has a mission of advancing late-stage cardiovascular innovations, i.e., """"""""shovel ready"""""""" opportunities with rapid job creation potential. The applicant consortium has now come together to address an unmet need by proposing a new Center (Cleveland Clinic Innovation Accelerator, CCIA) with an overall goal of propelling early-stage projects forward and educating researchers to be full partners in transforming their discoveries into high-impact advances in patient care. The proposed Center will enhance and coordinate the existing resources of the five partnering institutions to advance the very strong pipeline of laboratory discoveries and technical innovations generated every year in NHLBI mission areas (over 250 NHLBI-funded projects). This application has three specifics aims: (1) To create the CCIA - a self-sustainable, multi-institutional consortium focused on translating early innovations in NHLBI mission areas into advanced solutions for improving global patient care. CCIA will complement the mission of the GCIC by reaching earlier into the discovery and development pipeline in order to address the gap between discovery research and validation/pre-clinical development. (2) To select through rigorous peer-review commercially-promising NHLBI funded projects that will receive funds and expert project management. Projects shall span the technology range of diagnostics, devices, therapeutics and tools. (3) To create a nationally accessible institute for educating and mentoring researchers, clinicians and developers in biomedical innovation and entrepreneurism. The Center will provide experience-based training to cultivate a growing cadre of commercially successful innovators. Generation of the CCIA will thus create a self-sustainable engine for propelling a large pipeline of NHLBI-related research discoveries into advances in human health.

Public Health Relevance

Cleveland Clinic and its partners Case Western Reserve University, Cincinnati Children's Hospital Medical Center, The Ohio State University and University of Cincinnati propose to create a new Center, the Cleveland Clinic Innovation Accelerator with an overall of goal accelerating the advancement of NHLBI-related research discoveries and innovations into improvements in human health and educating researchers to be full partners in this translation process.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Rousche, Kathleen T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cleveland Clinic Lerner
Other Basic Sciences
Schools of Medicine
United States
Zip Code
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064
Antman, Elliott M; Di Corleto, Paul E; Freeman, Mason W et al. (2017) NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges. Nat Rev Drug Discov 16:663-664
Fukunishi, Takuma; Best, Cameron A; Sugiura, Tadahisa et al. (2017) Preclinical study of patient-specific cell-free nanofiber tissue-engineered vascular grafts using 3-dimensional printing in a sheep model. J Thorac Cardiovasc Surg 153:924-932
Collins, John M; Reizes, Ofer; Dempsey, Michael K (2016) Healthcare Commercialization Programs: Improving the Efficiency of Translating Healthcare Innovations From Academia Into Practice. IEEE J Transl Eng Health Med 4:3500107
Fukunishi, Takuma; Best, Cameron A; Sugiura, Tadahisa et al. (2016) Tissue-Engineered Small Diameter Arterial Vascular Grafts from Cell-Free Nanofiber PCL/Chitosan Scaffolds in a Sheep Model. PLoS One 11:e0158555
Travers, Joshua G; Kamal, Fadia A; Robbins, Jeffrey et al. (2016) Cardiac Fibrosis: The Fibroblast Awakens. Circ Res 118:1021-40
Bernardo, Bianca C; Blaxall, Burns C (2016) From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure. Heart Lung Circ 25:425-34
Hegde, Shailaja; Cancelas, Jose A (2016) Dissecting the metabolic pathways controlling platelet survival in vivo: are our platelets what they eat? Transfusion 56:1928-31
Grimberg, Brian T; Grimberg, Kerry O (2016) Hemozoin detection may provide an inexpensive, sensitive, 1-minute malaria test that could revolutionize malaria screening. Expert Rev Anti Infect Ther 14:879-83
Zhang, Yongyou; Desai, Amar; Yang, Sung Yeun et al. (2015) TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science 348:aaa2340